WO2023199091 - HETEROCYCLIC COMPOUND
National phase entry:
Publication Number
WO/2023/199091
Publication Date
19.10.2023
International Application No.
PCT/IB2022/053399
International Filing Date
12.04.2022
Title **
[English]
HETEROCYCLIC COMPOUND
[French]
COMPOSÉ HÉTÉROCYCLIQUE
Applicants **
TAKEDA PHARMACEUTICAL COMPANY LIMITED
1-1, Doshomachi 4-chome
Chuo-ku, Osaka-shi
Osaka, 541-0045, JP
Inventors
IKEDA, Shuhei
c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED
26-1, Muraoka-Higashi 2-chome, Fujisawa-shi
Kanagawa, 251-0012, JP
PAWLICZEK, Martin Alexander
c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED
26-1, Muraoka-Higashi 2-chome, Fujisawa-shi
Kanagawa, 251-0012, JP
KIMURA, Eiji
c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED
26-1, Muraoka-Higashi 2-chome, Fujisawa-shi
Kanagawa, 251-0012, JP
HATTORI, Yasushi
c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED
26-1, Muraoka-Higashi 2-chome, Fujisawa-shi
Kanagawa, 251-0012, JP
PIRA, Marilena
c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED
26-1, Muraoka-Higashi 2-chome, Fujisawa-shi
Kanagawa, 251-0012, JP
MIGUELEZ-RAMOS, Javier
c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED
26-1, Muraoka-Higashi 2-chome, Fujisawa-shi
Kanagawa, 251-0012, JP
TOKUNAGA, Norihito
c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED
26-1, Muraoka-Higashi 2-chome, Fujisawa-shi
Kanagawa, 251-0012, JP
MIYANOHANA, Yuhei
c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED
26-1, Muraoka-Higashi 2-chome, Fujisawa-shi
Kanagawa, 251-0012, JP
HOASHI, Yasutaka
c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED
26-1, Muraoka-Higashi 2-chome, Fujisawa-shi
Kanagawa, 251-0012, JP
KAJITA, Yuichi
c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED
26-1, Muraoka-Higashi 2-chome, Fujisawa-shi
Kanagawa, 251-0012, JP
ITO, Yoshiteru
c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED
26-1, Muraoka-Higashi 2-chome, Fujisawa-shi
Kanagawa, 251-0012, JP
KOIKE, Tatsuki
c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED
26-1, Muraoka-Higashi 2-chome, Fujisawa-shi
Kanagawa, 251-0012, JP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 3487 | |
| EPO | Filing, Examination | 17136 | |
| Japan | Filing | 594 | |
| South Korea | Filing | 482 | |
| USA | Filing, Examination | 15310 |
Total: 37009 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I) is useful as an agent for the prophylaxis or treatment of narcolepsy.[French]
Le problème décrit par la présente invention est de fournir un composé hétérocyclique ayant une activité agoniste sur le récepteur de l'orexine de type 2. A cet effet, l'invention concerne un composé représenté par la formule (I), qui est utile en tant qu'agent pour la prophylaxie ou le traitement de la narcolepsie.